# Avelumab and Radiation in Muscle-Invasive Bladder Cancer

> **NCT03747419** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 14 (actual)

## Conditions studied

- Bladder Cancer
- Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Avelumab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03747419
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-13
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** In agreement with the drug sponsor and the institution, the trial has been terminated due to slow accrual.
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747419, "Avelumab and Radiation in Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03747419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*